The collaboration between the companies is partly funded by the UK government’s Innovate UK business grant scheme alongside Singapore’s, Enterprise Singapore. Credit: Shutterstock / Antonio Guillem

An artificial intelligence (AI) driven remote monitoring system designed to predict exacerbations in asthmatic patients has gone into production as part of a deal between the UK and Singapore.

Singapore-based respiratory monitoring device firm, Aevice Health, is partnering with London-based Jiva.ai, to develop a remote patient monitoring platform that will allow people living with asthma to track their condition and predict asthma attacks.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The collaboration between the companies is partly funded by the UK government’s Innovate UK business grant scheme alongside Singapore’s, Enterprise Singapore. The system intends to utilise the already US Food and Drug Administration (FDA) approved AeviceMD, a wearable smart stethoscope that continuously monitors for asthma biomarkers.

Data compiled by the US Centre for Disease Control (CDC) published in the American Journal of Managed Care, details how asthma is estimated to cost $80bn annually. The same study also highlighted how between 2008 and 2013, asthma was responsible for $3bn in losses from missed work and school days, $29bn from asthma-related mortality, and $50.3bn in medical costs.

Aevice Health’s CTO, Rex Tan said: “Asthma is a global health concern, and our collaboration with Jiva.ai through the Enterprise Singapore and Innovate UK jointly funded co-innovation project aligns with our mission to empower individuals to actively manage their respiratory health.”

GlobalData’s Medical Device Intelligence Centre details how the majority of medical devices in the asthma space focus more on relief from asthmatic events with nebulizer devices making up the bulk of the market, with only Aevice Health working on bringing remote monitoring into the indication. A GlobalData study also found how in 2019 the remote patient monitoring market sat at an estimated worldwide value of approximately $600m, with that figure estimated to rise to $760m by 2030.

Additionally, the device is set to use Jiva.ai’s multimodal no-code AI, which the company says has the ability to read multiple different types of data and make predictions outside of clinical settings. The AI system is also intended to be designed as a ‘No-code’ AI, enabling non-technical users to build, deploy, and automate AI models without writing a single line of code.

Manish Patel, CEO at Jiva.ai said: “Combining Jiva.ai’s no-code AI platform with Aevice Health’s advanced remote patient monitoring platform is a significant leap forward in the realm of healthcare innovation.”

Elsewhere in the asthma space, the FDA has granted 510(k) clearance to NuvoAir for the in-home use of its Air Next spirometer, allowing individuals to conduct comprehensive lung function tests from their own homes. At the same time,  Scotland-based company 1nhalerraised £2m ($2.5m) to develop a single-use dry powder inhaler.